Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease

Journal of Managed Care Pharmacy

Volumn 15, Issue 9, 2009, Pages 741-750

  Horowitz, Jeffrey ^a   Agarwal, Anil ^b   Huang, Fannie ^c   Gitlin, Matthew ^d   Gandra, Shravanthi R ^c   Cangialose, Charles B ^c  

^a Truesdale Clinic   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

^d Amgen Research GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; POST HOC ANALYSIS; SINGLE BLIND PROCEDURE;

EID: 75149147300     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.9.741     Document Type: Article

References (33)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-47.
2. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002;162(12):1401-08.
3. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501-10.
4. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38(4):803-12.
5. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38(4):955-62.
6. Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant. 2000;15(5):650-58.
7. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;45(4):658-66.
8. Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8(6):629-38.
9. Aranesp U.S. package insert. Available at: http://www.aranesp.com/pdf/ aranesp-pi.pdf. Accessed November 9, 2009.
10. Epogen U.S. package insert. Available at: http://www.epogen.com/pdf/ epogen-pi.pdf. Accessed November 9, 2009.
11. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31(4):290-99.
12. Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet. 2006;45(5):503-10.
13. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25(8):2307-35.
14. Nissenson AR. Dosing darbepoetin alfa. Am J Kidney Dis. 2002;40(4):872.
15. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40(1):110-18.
16. Barron JJ, Grochulski WD, Mody SH, Bookhart B, McKenzie RS. Erythropoietic therapy: dosing patterns and calculated cost assessment for pre-dialysis chronic kidney disease patients in managed care setting. Pharm Ther. 2007;32(12):661-70.
17. Cremieux PY, Van Audenrode M, Lefebvre P. The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. Curr Med Res Opin. 2006;22(12):2329-36.
18. Duh MS, Mody SH, McKenzie RS, et al. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. Drugs Aging. 2006;23(12):969-76.
19. Duh MS, Mody SH, Scott McKenzie R, et al. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clin Ther. 2006;28(9):1443-50.
20. Hymes J, Bickimer T, Jackson JH, et al. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. Curr Med Res Opin. 2007;23(8):1931-37.
21. Laliberte F, Lefebvre P, Vekeman F, et al. Drug utilization and cost considerations of predialysis chronic kidney disease patients receiving erythropoiesis-stimulating agents through pharmacy benefits [abstract]. Am J Kidney Dis. 2008;51:a25, no 130. Poster presented at: National Kidney Foundation (NKF) Spring Clinical Meetings; April 2-6, 2008; Dallas, TX.
22. Lefebvre P, Laliberte F, Lafeuille MH, et al. Assessment of drug utilization patterns and costs for erythropoietic stimulating agents for patients with chronic kidney disease [abstract]. Am J Kidney Dis. 2008;51:a25, no 140. Poster presented at: National Kidney Foundation (NKF) Spring Clinical Meetings; April 2-6, 2008; Dallas, TX.
23. Mody SH, Padmanabhan V, McKenzie RS, Bookart BK. Epoetin alfa and darbepoetin alfa dosing patterns in pre-dialysis chronic kidney disease patients. [poster PUK5]. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting; May 20-24, 2006; Philadelphia, PA.
24. Papatheofanis F, Smith C, Mody S, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. Am J Ther. 2007;14(4):322-27.
25. Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin. 2006;22(5):837-42.
26. Smith J, He J, Mahoney A, et al. Hospital inpatient utilization of eopetin alfa (EPO) and darbepoetin alfa (Darb) in patients with cancer and predialysis chronic kidney disease (pCKD) [poster PCN6]. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting; May 20-24, 2006; Philadelphia, PA.
27. Vekeman F, Bailey RA, McKenzie RS, Herrera A, Lefebvre P. Comparison of Epoetin alfa (EPO) and darbepoetin alfa (DARB) dosing patterns and costs in a pre-dialysis chronic kidney disease (CKD) inpatient population [abstract]. J Am Soc Nephrol. 2008;18:323A, TH-PO942. Poster presented at: American Society of Nephrology (ASN) Annual Meeting; November 4-9, 2008; Philadelphia, PA.
28. Vekeman F, McKenzie RS, Lefebvre P, et al. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Am J Health Syst Pharm. 2007;64(18):1943-49.
29. ClinicalTrials.gov. Phase III clinical trial NCT00093977. Study to assess darbepoetin alfa in subjects with chronic kidney disease. Available at: http://clinicaltrials.gov/ct2/show/NCT00093977?term=NCT00093977&rank=1. Accessed November 9, 2009.
30. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol. 2000;11:A0828.
31. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens. 2001;10(6):785-92.
32. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther. 1992;51(1):76-89.
33. CMS. Rules and Regulations. Federal Register. 2004;69(219):65796- 97. Available at: http://www.cms.hhs.gov/quarterlyproviderupdates/downloads/ CMS1427FC-3.PDF. Accessed November 13, 2009.